There have been no new updates on the pharmaceutical development of ladostigil since 2019.[1] At this time, it was inphase 2clinical trials for Alzheimer's disease.[1]
^Weinstock M, Bejar C, Wang RH, et al. (2000). "TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease".Advances in Research on Neurodegeneration. pp. 157–69.doi:10.1007/978-3-7091-6301-6_10.ISBN978-3-211-83537-1.PMID11205137.{{cite book}}:|journal= ignored (help)
^Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy".Annals of the New York Academy of Sciences.1122 (1):155–68.Bibcode:2007NYASA1122..155W.doi:10.1196/annals.1403.011.PMID18077571.S2CID39753711.
^Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). "Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression".Psychopharmacology.160 (3):318–24.doi:10.1007/s00213-001-0978-x.PMID11889501.S2CID26001621.
^Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). "A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease".Progress in Neuro-psychopharmacology & Biological Psychiatry.27 (4):555–61.doi:10.1016/S0278-5846(03)00053-8.PMID12787840.S2CID21612561.
